SLGL (Sol-Gel Technologies) Risk Assessment


SLGL Sol-Gel Technologies Ltd SLGL
56 GF Score
Price $74.01
GF Value $65.57
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Sol-Gel Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sol-Gel Technologies is: High Risk: High uncertainty with risk-return tradeoff.

Sol-Gel Technologies  (NAS:SLGL) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sol-Gel Technologies Risk Assessment Related Terms

SLGL vs AVXL, FATE, FHTX: Risk Assessment Comparison

For the Biotechnology subindustry, Sol-Gel Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sol-Gel Technologies Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sol-Gel Technologies's Risk Assessment falls into.


SLGL
56GF Score
Sol-Gel Technologies Ltd SLGL
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sol-Gel Technologies (SLGL) Overvalued in 2026?

Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued. The current stock price of $74.01 is trading 12.9% above its estimated GF Value™ of $65.57. GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.

Key valuation signals for SLGL:

  • Risk Assessment:
  • GF Value™: $65.57 vs. price of $74.01 (12.9% above fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sol-Gel Technologies Business Description

Other Exchanges 4SG:Germany
Address 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
56GF Score

Get the complete analysis for SLGL

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$74.01
Price
$65.57
GF Value